Famed UP mangoes set to fly out, tickle taste buds across globe
Uttar Pradesh is likely to make a mark on the global fruit export map as its famed mangoes head to international markets including Singapore, Dubai, Saudi Arabia, United States, and the United Kingdom. This year, UP will target to export 100-150 tonnes of mangoes grown in the state, an official said.
'Last year, UP mango production was 6 million metric tonnes, against India's total 22 to 23 million metric tonnes. In 2024, overall UP export was pegged at 0.013%. This number is very likely to increase in 2025,' says T Damodaran, director, ICAR-Central Institute for Subtropical Horticulture (CISH).
Damodaran said, 'We plan to export mangoes to Singapore and UAE by sea so that a large quantity can be exported. Mangoes will be sent to the US and Japan by air from the West UP region like Bulandshahr and Meerut.'
Divisional commissioner, Lucknow, Roshan Jacob, on Friday interacted with exporters and mango growers, and directed state officials to extend all necessary facilities for mango exports using CISH-developed post-harvest and sea-route export technologies.
To accelerate this initiative, ICAR-Central Institute for Subtropical Horticulture (CISH), Lucknow held a high-level Exporters-Growers Business Meet-2025 at its Rehmankheda campus where Jacob emphasised the importance of tapping into the domestic market potential across various states in India.
Additionally, she instructed divisional officials to establish a nodal centre for export promotion at the state level. She asked the Mandi Parishad, Lucknow, to set up a one-stop centre to assist farmers with registration on APEDA's Hort-Net Portal.
Damodaran highlighted that the institute will provide technical and logistical support for the export of premium Dussheri and Chausa mango varieties to Singapore, Dubai, and other international destinations during their respective seasons.
He informed that CISH has developed dedicated clusters for Dussheri mangoes in Lucknow and Chausa in Siana (Bulandshahr), where farmers are now producing export-quality fruits under the Institute's technical guidance, using CISH-developed technologies to ensure superior quality and compliance with export standards.
Vinita Sudhanshu, general manager, APEDA (New Delhi), elaborated on the vital role APEDA plays in promoting the export of North Indian mangoes. She emphasised the importance of quality compliance, international certifications, and logistics readiness for successful exports.
Ajay Jain (IAS), the chief development officer (CDO) of Lucknow informed that packing houses in Lucknow, Amroha, and Saharanpur are fully operational and equipped for mango processing and export handling.
He was also tasked with coordinating with Indian Railways for train halts and facilitating marketing opportunities through hotel chains, railway outlets, and online platforms such as Zepto, BigBasket, Blinkit, and others.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
an hour ago
- News18
Protecting World's $1.5-Trillion Coastal Economies: 7th Edition Of ICDRI-2025 Opens In France
Last Updated: The two-day annual conference brings together governments, UN agencies and multilateral development banks to promote disaster-resilient infrastructure in the wake of climate change The mounting disaster risks faced by the world's most vulnerable coastal communities are at the forefront of the seventh edition of the International Conference on Disaster Resilient Infrastructure (ICDRI-2025), which began in Nice, France, on Friday. The crucial two-day conference, organised by the CDRI, will urge the global community to fast-track resilient infrastructure in the world's most vulnerable countries. This year's focus is on coastal communities, which contribute roughly $1.5 trillion to global GDP annually – a figure projected to rise to nearly $3 trillion by 2030. In addition, nearly 90% of goods moved globally are transported by sea. About 37% of the world's population lives within 100 km of the coast, where the population density is twice the global average. While all coastal areas face growing challenges, Small Island Developing States (SIDS) are especially vulnerable because of their remoteness and isolation, experts say. 'Coastal resilience is essential for safeguarding lives, livelihoods, and economies. The conference will bridge science, policy, and finance by bringing together global voices to address shared challenges and promote collective action, particularly for vulnerable coastal communities and SIDS. Being delivered in Europe for the first time, in partnership with the Government of France, the 7th edition of CDRI's annual conference will again foster inclusive dialogue and forge action-oriented partnerships to advance the cause of disaster-resilient infrastructure," said Amit Prothi, DG, Coalition for Disaster Resilient Infrastructure (CDRI). Launched by Prime Minister Narendra Modi during the United Nations Climate Action Summit on 23rd September 2019, in New York, CDRI is the second major global initiative launched by India after the International Solar Alliance. A global partnership between governments, UN agencies, multilateral development banks, the private sector, and academic institutions, it serves as a platform for generating and exchanging knowledge and providing technical support to member countries. Since its formation, CDRI has forged global partnerships with as many as 49 countries. Over the next two days, experts will discuss how coastal regions, especially SIDS, can be better equipped to withstand climate-induced hazards while ensuring economic stability. The CDRI will also launch a thought piece on Disaster-Resilient Infrastructure (DRI) for Coastal Regions at the inaugural session. Developed by expert groups, it will set the tone for discussions throughout the two-day event, including the broader third UN Ocean Conference (UNOC3) taking place in Nice from June 9-13. First Published:
Mint
4 hours ago
- Mint
Despite trade war, US drug companies turn to China for key cancer treatments
The drug industry has spent months going along with the Trump administration's efforts to move manufacturing and investment into the U.S., and to disentangle the U.S. and Chinese economies. A long list of big pharmaceutical firms have committed tens of billions of dollars to factories and research facilities in the U.S. In the past few months, though, U.S. pharma companies have simultaneously supercharged their interest in China-based biotechs, announcing what are likely to be the biggest deals ever for the rights to experimental medicines invented by Chinese companies. So far, the Trump administration has been silent on the deals, which are worth around $25 billion in upfront and potential milestone payments and seem to fly in the face of White House policy. The deals could one day result in new options for sick patients, but they also pose a major risk to U.S. biotech firms. The domestic drug pipeline relies on capital from Big Pharma, and now those funds may be going to start-ups in Shanghai, rather than Cambridge, Mass. The recent deals follow a successful trial result last year by U.S. biotech Summit Therapeutics of a new immunotherapy cancer drug it licensed from Chinese firm Akeso. In the trial, the drug outperformed Merck's top-selling Keytruda, raising hopes that it could prove a major advancement in cancer treatment. Since then, Big Pharma companies have rushed to get their own drugs to compete with Summit's product. There was one deal in November, when Merck licensed an experimental drug from a Chinese drugmaker for around $500 million up front and another $2.7 billion in potential milestone payments. The biggest deals have come in just the past two weeks. In mid May, Pfizer said it would pay the Chinese biotech 3SBio $1.3 billion up front for its own competitor to the Summit drug, plus billions more in potential milestone payments. Pfizer is also making a $100 million equity investment in 3SBio. This past week, Bristol Myers Squibb said it would pay $3.5 billion over the next three years, plus billions more in potential milestone payments, for half the rights to a similar drug developed by a Chinese company called Biotheus, which German biotech BioNTech acquired a few months ago. These numbers would be big for any biotech licensing deal—the drugs remain far from approval. For Chinese-developed drugs, the payment sizes are unprecedented. 'These are pretty sophisticated companies allocating major capital here," says Craig Garthwaite, a professor and director of the program on healthcare at Northwestern University's Kellogg School of Management, of the latest deals. 'It's demonstrating the validity of the science." It's all happening while Big Pharma is doing its best to show the Trump administration that it can adapt to the president's agenda, as the industry seeks to head off threatened tariffs and drug price limits. Eli Lilly, Johnson & Johnson, Bristol Myers, and others have all announced tens of billions of dollars in planned U.S. investments in manufacturing and research facilities this year. The White House didn't respond to a request for comment. Washington has been increasingly anxious about the rapid development of China's biotech ecosystem. The Biosecure Act, which hasn't passed Congress, targets complex drug manufacturing in China, while a recent report commissioned by Congress called on the U.S. to take 'swift action" to compete with the Chinese biotech sector. Amid those stalled efforts, the pace of Chinese biotech innovation is picking up. Until recently, the U.S. drug industry had largely seen Chinese biotechs as a source for cheaper 'me too" assets, which echo but don't duplicate existing medicines. Now, with the latest cancer drug deals, Chinese companies are innovating a new class of drugs that every Big Pharma firm seems to think it needs to get in on. The Summit drug that got investors, analysts, and companies excited last year is known as a PD-1/VEGF bispecific antibody, which combines two proven cancer-fighting tools. Daina Graybosch, an analyst at Leerink Partners, says that companies in the U.S. and Europe have been experimenting with similar combinations, but never tested them in humans. That's because early-stage human tests are cheaper and easier to run in China than the U.S. All but the largest U.S. biotechs generally develop just one or two experimental medicines at a time, while Chinese biotechs of a similar size 'could have a dozen" different drugs in trials, according to Cantor Fitzgerald analyst Li Watsek. The combination cancer drugs ultimately weren't exciting enough for the U.S. biotechs to prioritize. But Chinese companies moved forward with different variations. When Summit and its Chinese partner got promising results on an antibody that combined PD-1 and VEGF, there were multiple other Chinese biotechs with their own PD-1/VEGF combinations ready to of this is great news for the U.S. biotech sector, which has been battered in recent years by declining share prices, cash shortfalls, and other challenges. Over the past 12 months, the SPDR S&P Biotech exchange-traded fund is down 11.5%, versus a gain of 11.7% for the S&P 500. Watsek says that part of the problem for investors is that it's hard to know what Chinese biotechs are actually working on. 'Right now it's a little bit of a black box, because a lot of these Chinese companies, they may have assets, but it's impossible to track," she says. 'There could be a dozen molecules that are in development that you may not have even heard of." Over the long term, the worries get potentially more complex. 'At some point, it's going to get terminal velocity, and we're going to have a very dangerous competitor next to us," says Joseph Grogan, a senior policy official during the first Trump administration who is now a nonresident senior scholar at the USC Schaeffer Institute. 'If the Chinese establish the flywheel of the ecosystem that we built—of private-sector companies, research and development, government support, and strong but prudent regulatory foundation—then we're cooked." Write to Josh Nathan-Kazis at
Time of India
7 hours ago
- Time of India
If Elon Musk and Donald Trump were in a reality show together: What would it look like?
Donald Trump and Elon Musk If there's one thing America loves more than a good barbecue, it's a reality show that serves up drama, ego, and questionable fashion choices. Enter Elon Musk and Donald Trump , the dynamic duo, now starring in the reality series we never asked for but desperately need. Episode 1: "The Big Beautiful Bill Blow-Up" The season kicks off with Trump unveiling his latest legislative masterpiece, the "One Big Beautiful Bill Act." Musk, ever the contrarian, takes to X (formerly Twitter) to call it a "disgusting abomination." The bill, which slashes EV subsidies and balloons the deficit, becomes the perfect storm for their first major fallout. Cue the dramatic music as Trump responds, calling Musk "ungrateful" and threatening to revoke federal contracts. Musk fires back with a tweet alleging Trump's name appears in the Epstein files. The internet collectively gasps. Episode 2: "DOGE Days Are Over" Flashback to 2024: Trump, in a moment of what can only be described as a fever dream, appoints Musk to lead the Department of Government Efficiency (DOGE). The goal? To dismantle bureaucracy and delete inefficiency. Musk, ever the meme lord, suggests the department's final act should be to "delete itself." by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch CFD với công nghệ và tốc độ tốt hơn IC Markets Đăng ký Undo Fast forward to 2025: Musk exits DOGE, citing the need to focus on his companies. Trump, ever the supportive boss, says Musk isn't really leaving. The audience wonders if this is the beginning of the end or just another plot twist. Episode 3: "The Space Race Showdown" Musk, not one to shy away from a challenge, threatens to decommission SpaceX 's Dragon spacecraft in retaliation for Trump's policies. The stakes are high as NASA operations hang in the balance. Will Musk go through with it, or is this just another empty threat? Episode 4: "Bannon's Bombshell" Enter Steve Bannon, the wildcard of the season. He calls Musk a "parasitic illegal immigrant" and accuses him of being a "racist" and "an agent of Chinese influence." The feud between Musk and Trump reaches new heights as Bannon stirs the pot, adding fuel to the fire. Episode 5: "The Impeachment Ultimatum" Musk, not one to back down, suggests Trump's impeachment and hints at supporting JD Vance as a replacement. The political landscape shifts as allies on both sides join the fray. The audience is left on the edge of their seats, wondering what will happen next. Episode 6: "Silicon Valley's Split" The tech world watches in suspense as Silicon Valley picks sides. Some investors back Musk's economic concerns, while others remain silent or ambiguous. The division signals a potential schism between the tech industry's right-leaning factions and traditional conservatives. Episode 7: "The Great American Fair" In a surprising twist, Trump announces the "Great American Fair" to celebrate the 250th anniversary of the United States. The event promises to be a spectacle, but will Musk be involved, or has their partnership reached its final chapter? Season Finale: "The Mars Mission" As the season concludes, Musk hints at launching a new political party and doubles down on his Mars colonization plans. Trump, ever the showman, teases a potential collaboration. The audience is left wondering: will they join forces for the ultimate reality show crossover, or is this the end of their saga?
